Search | VHL Regional Portal

Transition from intravenous treprostinil to enteral selexipag in an infant with pulmonary arterial hypertension.

Koo, Rachel; Lo, Jennifer; Bock, Matthew J.

Cardiol Young ; 29(6): 849-851, 2019 Jun.

Article in English | MEDLINE | ID: mdl-31379316

ABSTRACT

Selexipag is an enteral, selective prostacyclin IP receptor agonist approved for pulmonary hypertension in adults. There are few reports of its use in children and none in infants. We report the first transition of an infant (11.5 months, 8.6 kg) from intravenous treprostinil (40 ng/kg/minute) to enteral selexipag (400 mcg twice daily) with a good response and no adverse effects.

Subject(s)

Acetamides/administration & dosage , Epoprostenol/analogs & derivatives , Pulmonary Arterial Hypertension/drug therapy , Pulmonary Wedge Pressure/drug effects , Pyrazines/administration & dosage , Administration, Intravenous , Administration, Oral , Antihypertensive Agents/administration & dosage , Echocardiography , Enteral Nutrition , Epoprostenol/administration & dosage , Humans , Infant, Newborn , Infusions, Intravenous , Male , Pulmonary Arterial Hypertension/diagnosis , Pulmonary Arterial Hypertension/physiopathology , Receptors, Prostaglandin

ABSTRACT

Subject(s)

SEND TO:

SELECTION OF CITATIONS

SEARCH DETAIL